Sight Diagnostics, the company behind the first FDA-cleared direct-from-fingerstick Complete Blood Count (CBC) analyzer, has raised $71 million in Series D funding with participation from Koch Disruptive Technologies, Longliv Ventures and OurCrowd. This new round brings Sight’s total funding to more than $124 million and will support the expansion of Sight’s commercial operations globally and advance Sight’s R&D into the detection of additional diseases as well as biomarkers indicating COVID-19 severity.

Read more here.